Biogenes Technologies
Seongnam, South Korea· Est.
South‑Korean biotech delivering animal‑free aptamer reagents for research and diagnostics.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
South‑Korean biotech delivering animal‑free aptamer reagents for research and diagnostics.
Technology Platform
Synthetic, chemically‑stabilised nucleic‑acid aptamers generated via proprietary SELEX‑derived workflows, offering high affinity and specificity without animal immunisation.
Opportunities
Growing demand for ethical, reproducible binding reagents and the expansion of point‑of‑care diagnostic markets present clear growth pathways.
Risk Factors
Limited market awareness of aptamer technology and competition from established antibody suppliers could hinder adoption.
Competitive Landscape
Biogenes competes with niche aptamer firms and large antibody manufacturers; its differentiation lies in animal‑free production and rapid custom‑design capabilities.